Clinical Trial · NCT07087197

A Study of SKB107 in Advanced Solid Tumors With Bone Metastases

Overview

A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of SKB107 in subjects with advanced solid tumors with bone metastases.

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Phase

Phase 1

Contacts

Yina Diao (CONTACT)

diaoyina@kelun.com

028-67252634

ClinicalTrials.gov

NCT07087197

Drug / Compound

IBA

Isotope(s):

Target(s):

Bone Metabolism

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

The Eastern Cooperative Oncology Group (ECOG) performance status score should be ≤ 1;
Phase Ib: Subjects with advanced mCRPC diagnosed by histology or cytology;
Have adequate organ and bone marrow functions;
Phase Ia: Subjects with advanced solid tumor bone metastases diagnosed by histology or cytology; and the subjects have failed standard treatment, or have no standard treatment, or are intolerant or not applicable to standard treatment;

Exclusion

Known spinal cord compression, or clinical imaging manifestations suggesting impending spinal cord compression.
Known "super bone imaging".
Subjects with a history of radionuclide/radioactive drug allergy, or allergic to any component of the study formulation.